Fdg pet for evaluating the change of glucose metabolism in prostate cancer after androgen ablation

Nuclear Medicine Communications

Volumn 22, Issue 9, 2001, Pages 963-969

  Oyama, N ^a   Akino, H ^a   Suzuki, Y ^a   Kanamaru, H ^a   Ishida, H ^a   Tanase, K ^a   Sadato, N ^a   Yonekura, Y ^a   Okada, K ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Endocrine therapy; FDG PET; Prostate cancer

Indexed keywords

ANDROGEN; ANTIANDROGEN; FLUORODEOXYGLUCOSE F 18; HORMONE;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER TISSUE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFECT; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; HORMONAL THERAPY; HUMAN; MALE; METASTASIS; ORGAN SIZE; POSITRON EMISSION TOMOGRAPHY; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; TREATMENT OUTCOME; TUMOR VOLUME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; FLUORODEOXYGLUCOSE F18; GLUCOSE; GOSERELIN; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034873911     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200109000-00004     Document Type: Review

References (19)

1. Mineura K, Yasuda T, Kowada M, et al. Positron emission tomographic evaluation of radiochemotherapeutic effect on regional cerebral hemocirculation and metabolism in patients with gliomas. J Neurooncol 1987; 5: 277-285.
2. Lowe VJ, Hebert ME, Hawk TC, Anscher MS, Coleman RE. Chest wall FDG accumulation in serial FDG-PET images in patients being treated for bronchogenic carcinoma. J Nucl Med 1994; 35: 76P.
3. Effert PJ, Bares R, Handt S, et al. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18-fluorine-labeled deoxyglucose. J Urol 1996; 155: 994-998.
4. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 1996; 199: 751-756.
5. Yeh SDJ, Imbriaco M, Garza D, et al. Twenty percent of bony metastases of hormone resistant prostate cancer are detected by FDG-PET whole body scanning. J Nucl Med 1995; 36: 198P.
6. Oyama N, Akino H, Suzuki Y, et al. The increased accumulation of 18-fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol 1999; 29: 623-629.
7. Agus DB, Golde DW, Sgouros G, et al. Positron emission tomography of a human prostate xenograft: Association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. Cancer Res 1998; 58: 3009-3014.
8. Gleason DF, Veterans Administration Cooperative Urological Research Group. Histologic grading and clinical staging of carcinoma of the prostate in urologic pathology. In: Tannenbaum M (ed). The prostate. Philadelphia: Lea & Febiger, 1997: 170-197.
9. Sobin LH, Wittekind Ch (eds). TNM classification of malignant tumors, 5th edition. New York: Wiley-Liss, 1997.
10. Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27: 235-238.
11. DeGrado TR, Turkington TG, Williams JJ, et al. Performance characteristics of a whole-body PET scanner. J Nucl Med 1994; 35: 1398-1406.
12. Habekorn U, Bellemann ME, Altmann A, et al. PET 2-fluoro-2-deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with gemcitabine. J Nucl Med 1997; 38: 1215-1221.
13. Hoe CK, Rosen PJ, Belldegrun A, et al. Quantitative and whole body FDG PET in the evaluation of suramine therapy in patients with metastatic prostate cancer. J Nucl Med 1996; 37: 267P.
14. Liu IJ, Zafar MB, Lai Y, Segall LG, Terris MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001; 57: 108-111.
15. Seltzer MA, Barbaric Z, Belldegrun A, et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 1999; 162: 1322-1328
16. Cheryl TE, Joseph EO. Diagnostic markers of prostate cancer: utility of prostate-specific antigen in diagnosis and staging. Semin Surg Oncol 1995; 11: 23-25.
17. Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990; 50: 3748-3753.
18. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996; 28: 251-265.
19. Eisenberger MA, Nelson WG. How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution! J Natl Cancer Inst 1996; 88: 779-781.